{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:23:37Z","timestamp":1791329017830,"version":"4.3.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012905","name":"Department of Science and Technology of Shandong Province","doi-asserted-by":"publisher","award":["ts202408375"],"award-info":[{"award-number":["ts202408375"]}],"id":[{"id":"10.13039\/100012905","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["12475343"],"award-info":[{"award-number":["12475343"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["academicradiology.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Academic Radiology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.acra.2025.11.009","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T20:41:42Z","timestamp":1764016902000},"page":"1167-1179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Identifying Patients with EGFR-Mutated Oligometastatic NSCLC Suitable for Third-Generation EGFR-TKI Combined with Thoracic Radiotherapy Using Nomograms Based on CT Radiomic and Clinicopathological Factors"],"prefix":"10.1016","volume":"33","author":[{"given":"Xinhang","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxiao","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2962-0820","authenticated-orcid":false,"given":"Chengxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acra.2025.11.009_bib1","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.acra.2025.11.009_bib2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.acra.2025.11.009_bib3","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.acra.2025.11.009_bib4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","article-title":"Toward personalized treatment approaches for non-small-cell lung cancer","volume":"27","author":"Wang","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.acra.2025.11.009_bib5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrc3775","article-title":"Non-small-cell lung cancers: a heterogeneous set of diseases","volume":"14","author":"Chen","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.acra.2025.11.009_bib6","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1200\/JCO.2010.32.6181","article-title":"Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas","volume":"29","author":"D'Angelo","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acra.2025.11.009_bib7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.6004\/jnccn.2021.0013","article-title":"NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021","volume":"19","author":"Ettinger","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.acra.2025.11.009_bib8","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1200\/JCO.21.02641","article-title":"AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as first-line therapy for locally advanced or metastaticnon-small-cell lung cancer with EGFR Exon 19 deletion or L858R mutations","volume":"40","author":"Lu","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acra.2025.11.009_bib9","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","article-title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.acra.2025.11.009_bib10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acra.2025.11.009_bib11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.acra.2025.11.009_bib12","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.acra.2025.11.009_bib13","first-page":"336","article-title":"Radiation dose effect in locally advanced non-small cell lung cancer","volume":"6","author":"Kong","year":"2014","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.acra.2025.11.009_bib14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acra.2025.11.009_bib15","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","article-title":"Oligometastases revisited","volume":"8","author":"Weichselbaum","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.acra.2025.11.009_bib16","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.acra.2025.11.009_bib17","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized trial of first-line Tyrosine Kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer","volume":"115","author":"Wang","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.acra.2025.11.009_bib18","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.23.02075","article-title":"Thoracic radiotherapy improves the survival in patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors: a multicenter, randomized, controlled, Phase III trial","volume":"43","author":"Sun","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acra.2025.11.009_bib19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jtho.2024.09.1431","article-title":"Radiomics-based support vector machine distinguishes molecular events driving the progression of lung Adenocarcinoma","volume":"20","author":"Li","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.acra.2025.11.009_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217872","article-title":"AI-based radiomic features predict outcomes and the added benefit of chemoimmunotherapy over chemotherapy in extensive stage small cell lung cancer: A multi-institutional study","volume":"628","author":"Khorrami","year":"2025","journal-title":"Cancer Lett"},{"key":"10.1016\/j.acra.2025.11.009_bib21","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jtho.2016.11.2226","article-title":"Radiomic-based pathological response prediction from primary tumors and lymph nodes in NSCLC","volume":"12","author":"Coroller","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.acra.2025.11.009_bib22","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jtho.2016.11.2225","article-title":"EGFR mutation subtypes influence survival outcomes following first-line gefitinib therapy in advanced Asian NSCLC Patients","volume":"12","author":"Sutiman","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.acra.2025.11.009_bib23","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.jtcvs.2017.06.062","article-title":"Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma","volume":"154","author":"Takamochi","year":"2017","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.acra.2025.11.009_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.719919","article-title":"Machine learning-based CT Radiomics analysis for prognostic prediction in metastatic non-small cell lung cancer patients with EGFR-T790M mutation receiving third-generation EGFR-TKI Osimertinib treatment","volume":"11","author":"Tang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.acra.2025.11.009_bib25","first-page":"2302075","article-title":"Thoracic radiotherapy improves the survival in patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors: a multicenter, randomized, controlled, Phase III trial","author":"Sun","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acra.2025.11.009_bib26","article-title":"Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.acra.2025.11.009_bib27","doi-asserted-by":"crossref","DOI":"10.2214\/AJR.24.31675","article-title":"Habitat imaging with Tumoral and Peritumoral Radiomics for prediction of lung adenocarcinoma invasiveness on preoperative chest CT: a multicenter study","volume":"223","author":"Shang","year":"2024","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.acra.2025.11.009_bib28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1136\/thorax-2023-220226","article-title":"Radiomics analysis to predict pulmonary nodule malignancy using machine learning approaches","volume":"79","author":"Warkentin","year":"2024","journal-title":"Thorax"},{"key":"10.1016\/j.acra.2025.11.009_bib29","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00330-022-09123-5","article-title":"Prognostic analysis and risk stratification of lung adenocarcinoma undergoing EGFR-TKI therapy with time-serial CT-based radiomics signature","volume":"33","author":"Zhang","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1016\/j.acra.2025.11.009_bib30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40644-023-00522-5","article-title":"A radiomics-based deep learning approach to predict progression free-survival after tyrosine kinase inhibitor therapy in non-small cell lung cancer","volume":"23","author":"Lu","year":"2023","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.acra.2025.11.009_bib31","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.acra.2025.11.009_bib32","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.lungcan.2014.01.006","article-title":"EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?","volume":"84","author":"Hendriks","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.acra.2025.11.009_bib33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","article-title":"The changing treatment landscape of EGFR-mutant non-small-cell lung cancer","volume":"22","author":"Zhou","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.acra.2025.11.009_bib34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ijc.21496","article-title":"Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers","volume":"118","author":"Shigematsu","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.acra.2025.11.009_bib35","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10654-021-00752-6","article-title":"Systemic inflammation markers and cancer incidence in the UK Biobank","volume":"36","author":"N\u00f8st","year":"2021","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.acra.2025.11.009_bib36","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.1111\/cas.15964","article-title":"Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non-small cell lung cancer patients with neoadjuvant immunotherapy","volume":"114","author":"Huai","year":"2023","journal-title":"Cancer Sci"},{"key":"10.1016\/j.acra.2025.11.009_bib37","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12890-022-01901-7","article-title":"The MLR, NLR, PLR and D-dimer are associated with clinical outcome in lung cancer patients treated with surgery","volume":"22","author":"Wang","year":"2022","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.acra.2025.11.009_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004688","article-title":"Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy","volume":"10","author":"Hwang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.acra.2025.11.009_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113588","article-title":"Machine learning identifies immune-based biomarkers that predict efficacy of anti-angiogenesis-based therapies in advanced lung cancer","volume":"143","author":"Chen","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.acra.2025.11.009_bib40","article-title":"Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer","volume":"14","author":"Zheng","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.acra.2025.11.009_bib41","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13062-025-00674-3","article-title":"Prognostic model integrating histology, systemic inflammation, and recurrence status predicts immunotherapy response in advanced non-small-cell lung cancer patients","volume":"20","author":"Moiseenko","year":"2025","journal-title":"Biol Direct"},{"key":"10.1016\/j.acra.2025.11.009_bib42","article-title":"The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 \u2265 50% advanced non-small-cell lung cancer","volume":"6","author":"Banna","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.acra.2025.11.009_bib43","article-title":"Development and validation of a survival prediction model for patients with advanced non-small cell lung cancer based on LASSO regression","volume":"15","author":"Guo","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.acra.2025.11.009_bib44","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/IJGM.S174605","article-title":"The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small cell lung cancer patients treated with EGFR TKI","volume":"11","author":"Phan","year":"2018","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.acra.2025.11.009_bib45","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ccell.2019.02.009","article-title":"Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets","volume":"35","author":"Cassetta","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.acra.2025.11.009_bib46","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1158\/0008-5472.CAN-04-3547","article-title":"Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva)","volume":"65","author":"Chinnaiyan","year":"2005","journal-title":"Cancer Res"}],"container-title":["Academic Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633225010621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633225010621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T13:14:41Z","timestamp":1773926081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1076633225010621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1076633225010621"],"URL":"https:\/\/doi.org\/10.1016\/j.acra.2025.11.009","relation":{},"ISSN":["1076-6332"],"issn-type":[{"value":"1076-6332","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying Patients with EGFR-Mutated Oligometastatic NSCLC Suitable for Third-Generation EGFR-TKI Combined with Thoracic Radiotherapy Using Nomograms Based on CT Radiomic and Clinicopathological Factors","name":"articletitle","label":"Article Title"},{"value":"Academic Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acra.2025.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Association of Academic Radiology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}